Literature DB >> 10622595

Early predictors of response to treatment in patients with chronic hepatitis C.

M P Civeira1, J Prieto.   

Abstract

The term sustained response should be applied to patients with negative serum HCV-RNA and normal values of serum transaminases 6 months after interferon withdrawal. To investigate which factors identify sustained responders early during treatment we analysed 18 reports which used the definition sustained response. Eight reports, comprising 988 patients, have studied the value of early clearance of viraemia as a predictor of sustained response using multivariate analysis and all of them found that this was the strongest predictor of a sustained response. Determination of HCV-RNA 4 or 12 weeks after initiation of IFN therapy predicts treatment outcome more accurately than baseline viral load (the best pre-treatment predictor). ALT levels during the first 12 weeks of treatment have lower predictive value than early viral clearance. The sensitivity of a negative HCV-RNA test is similar at week 4 and at week 12 of therapy while the specificity and the accuracy is higher at week 4. The value of persistent viraemia for early prediction of no response is higher than 97%, with similar values at weeks 4 and 12. Persistence of HCV-RNA in serum at week 4 strongly indicates that the patient will not respond to treatment and in these cases interruption of treatment or other therapeutic options could be considered.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10622595     DOI: 10.1016/s0168-8278(99)80409-7

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  9 in total

1.  A model of patient choice with mid-therapy information.

Authors:  William C Grant; Teresa L Kauf
Journal:  Patient       Date:  2009-09-01       Impact factor: 3.883

2.  Hepatitis C virus (HCV) RNA determination after two weeks of induction interferon treatment is an accurate predictor of nonresponse: comparison of two treatment schedules.

Authors:  A Rossini; M Artini; M Levrero; C Almerighi; M Massari; L Biasi; E Radaeli; E Cariani
Journal:  Dig Dis Sci       Date:  2001-11       Impact factor: 3.199

3.  Benefit of hepatitis C virus core antigen assay in prediction of therapeutic response to interferon and ribavirin combination therapy.

Authors:  Masahiko Takahashi; Hidetsugu Saito; Makiko Higashimoto; Kazuhiro Atsukawa; Hiromasa Ishii
Journal:  J Clin Microbiol       Date:  2005-01       Impact factor: 5.948

4.  Treatment of chronic hepatitis C in a Canadian Aboriginal population: results from the PRAIRIE study.

Authors:  Gerald Y Minuk; Meaghan O'Brien; Kim Hawkins; Didi Emokpare; James McHattie; Paul Harris; Lawrence Worobetz; Karen Doucette; Kelly Kaita; Stephen Wong; Gilles Pinette; Julia Uhanova
Journal:  Can J Gastroenterol       Date:  2013-12       Impact factor: 3.522

5.  Alanine aminotransferase normalization at week 8 predicts viral response during hepatitis C treatment.

Authors:  Umit Bilge Dogan; Mustafa Salih Akin; Serkan Yalaki
Journal:  World J Gastroenterol       Date:  2013-12-14       Impact factor: 5.742

6.  Rapid normalization of alanine aminotransferase predicts viral response during combined peginterferon and ribavirin treatment in chronic hepatitis C patients.

Authors:  Yun Jung Kim; Byoung Kuk Jang; Eun Soo Kim; Kyung Sik Park; Kwang Bum Cho; Woo Jin Chung; Jae Seok Hwang
Journal:  Korean J Hepatol       Date:  2012-03-22

7.  Kinetics of hepatitis C virus RNA load during pegylated interferon alpha-2a and ribavirin treatment in naïve genotype 1 patients.

Authors:  Denis Ouzan; Hacène Khiri; Guillaume Pénaranda; Hélène Joly; Philippe Halfon
Journal:  Comp Hepatol       Date:  2005-12-21

8.  Factors associated with rapid and early virologic response to peginterferon alfa-2a/ribavirin treatment in HCV genotype 1 patients representative of the general chronic hepatitis C population.

Authors:  M Rodriguez-Torres; M S Sulkowski; R T Chung; F M Hamzeh; D M Jensen
Journal:  J Viral Hepat       Date:  2009-08-05       Impact factor: 3.728

9.  Clinical Utility of a New Automated Hepatitis C Virus Core Antigen Assay for Prediction of Treatment Response in Patients with Chronic Hepatitis C.

Authors:  Mi Na Kim; Hyon Suk Kim; Ja Kyung Kim; Beom Kyung Kim; Seung Up Kim; Jun Yong Park; Do Young Kim; Sang Hoon Ahn; Kwang Hyub Han
Journal:  J Korean Med Sci       Date:  2016-09       Impact factor: 2.153

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.